Morning Glory Sciences– Author –
-
[Introductory In vivo CAR-T Series #3] Key to Precision and Safety: Designing Smart CAR Expression
In this third installment of our introductory series on in vivo CAR-T, we focus on a vital component for realizing safe and effective therapy: the design of CAR expression. In this third installment of our introductory series on in vivo ... -
【Introductory In vivo CAR-T Series #2】The Technologies Behind In Vivo CAR-T: mRNA, Vectors, and Promoters
In the first installment of our series, we introduced the revolutionary CAR-T cell therapy through the moving story of Emily Whitehead. In the first installment of our series, we introduced the revolutionary CAR-T cell therapy through th... -
[Introductory In Vivo CAR-T Series #1] The Miracle of Emily: What Is CAR-T Therapy?
CAR-T cell therapy has emerged as a groundbreaking treatment that specifically targets cancer cells. Among its forms, the “in vivo type” CAR-T—where the therapeutic process happens inside the body—is gaining attention as a next-generatio... -
ADC Series – Bonus Chapter: Breakthroughs and the Fierce Global Race for Next-Generation Antibody-Drug Conjugates
Over the past few years, the landscape of Antibody-Drug Conjugates (ADCs) has undergone a dramatic transformation, shifting from a niche therapeutic approach to a central pillar of oncology innovation. Over the past few years, the landsc... -
ADC Series Part 4: Mechanism of Drug Release and Intracellular Action in Tumor Cells
Antibody-drug conjugates (ADCs) deliver highly potent cytotoxic agents specifically to cancer cells, representing a breakthrough in targeted therapy. This article explains the final stage of ADC function—how the linker system releases th... -
ADC Series Part 3: Antibody Structure and Target Recognition — The Role of the Variable Region
In Antibody-Drug Conjugates (ADCs), antibodies serve as targeting agents that deliver drugs to cancer cells. This article focuses on the "Variable Region," the key structure that enables antibodies to specifically recognize cancer antige... -
Part 2: Basic Structure and Components of ADCs — Understanding the Role of Antibody, Linker, and Payload
Antibody-drug conjugates (ADCs) are next-generation therapeutics gaining attention, especially in oncology. Antibody-drug conjugates (ADCs) are next-generation therapeutics gaining attention, especially in oncology. In this second part, ... -
Beginner-Friendly Intro Series
Summer Special｜Beginner-Friendly Intro Series Vol.2 (Part 1)What Are Antibodies? The Origin Story of ADCs – A Precision Cancer Weapon Welcome to Part 1 of our Summer Special Beginner Series Vol.2 on Morningglorysciences.This time, we’ll... -
Beginner-Friendly Intro Series
Summer Special｜Beginner-Friendly Intro Series Vol.1 (Part 2)Are They Safe? Global Competition and the Future of Anti-Obesity Drugs In Part 1, we explored what anti-obesity medications are, how GLP-1 works, and the key players in the cur... -
Beginner-Friendly Intro Series
Summer Special｜Beginner-Friendly Intro Series Vol.1 (Part 1)What Are Slimming Drugs? A Gentle Introduction to Anti-Obesity Medications Welcome to the Morningglorysciences Summer Special Beginner Series!This series is designed for reader... -
Aging & Rejuvenation Research Series Vol.4: The Nine Hallmarks of Stem Cell Aging
[Review] A Landmark Overview on Stem Cell Aging, Cell Stem Cell 2025 Introduction As we age, one of the most fundamental biological changes is the decline in stem cell function. As we age, one of the most fundamental biological changes i... -
BPI Technology: A Site-Specific Strategy That Could Reshape Targeted Protein Degradation
BPI Technology Advances Targeted Protein Degradation — A Site-Specific Strategy to Accelerate Drug Discovery Introduction Targeted protein degradation (TPD) has emerged as a transformative strategy in drug discovery, offering a means to ... -
CD388 (Cidara): What “One-Shot Seasonal Flu Protection” Could Mean for Vaccine Strategy
A New Era in Flu Prevention? — CD388 Shows One-Shot Seasonal Protection Introduction Flu prevention has long relied on seasonal vaccines, but a new innovation may challenge that paradigm. CD388, a long-acting antiviral developed by Cidar... -
Aging, Rejuvenation and Regeneration Series Vol. 3: Is the Brain the Master Regulator of Aging?
New Hypothesis Links Stress, the Brain, and Systemic Aging In the June 2025 issue of Nature (Vol.642), researchers from Columbia University led by Dr. Martin Picard proposed that senescent cells—those associat In the June 2025 issue of N... -
How Did Japanese Pharma Choose and Compete Globally? — A 2015–2025 Strategic Overview
Introduction Over the past decade, major Japanese pharmaceutical companies have undergone significant evolution amidst global competition. Over the past decade, major Japanese pharmaceutical companies have undergone significant evolution... -
What Did Big Pharma Bet On? — Technology and Therapeutic Trends Seen Through 2015–2025 M&A and Partnerships
Introduction Between 2015 and 2025, global pharmaceutical giants have expanded into innovative therapeutic areas and pursued internalization or adoption of novel technologies. Between 2015 and 2025, global pharmaceutical giants have expa... -
Rare & Pediatric Disease News Vol.4: Organoid-Based Discovery for UBA5-Linked Pediatric Epileptic Encephalopathy
Screenshot Human Brain Organoids Reveal Therapeutic Potential for Rare Pediatric Epilepsy In June 2025, a research team led by Dr. In June 2025, a research team led by Dr. Heather Mefford at St. Jude Children’s Research Hospital reported... -
Oncology Drug Approval News Flash: Sunvozertinib (Zegfrovy) Approved for EGFR Exon20 Insertion-Positive NSCLC
[FDA Accelerated Approval] New Oral TKI for Advanced NSCLC with EGFR Exon20 Insertions On July 2, 2025, the FDA granted accelerated approval to Sunvozertinib (brand name: Zegfrovy) for the treatment of adult patients with locally advance... -
Oncology Drug Approval News Flash: FDA Grants Accelerated Approval to Lynozyfic (linvoseltamab) for Relapsed/Refractory Multiple Myeloma
[FDA Approval] BCMA/CD3 Bispecific Antibody Approved on July 2, 2025 On July 2, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to linvoseltamab (brand name: Lynozyfic) for the treatment of adults with rela... -
[Science News] Cancer Discovery Perspective: Restoring Tumor Suppressor Function of Mutant p53 via Small Molecules
A study published in the June 2025 issue of Cancer Discovery reports a novel small-molecule strategy to restore the tumor suppressor function of mutant p53 proteins. A study published in the June 2025 issue of Cancer Discovery reports a ...
